Centre for Probe Development and Commercialization

The Centre for Probe Development and Commercialization is tackling Canada’s growing health care needs and introducing groundbreaking innovations to the Canadian molecular imaging market. From reliably meeting daily demands for Glucovision® (18F-FDG), to developing and commercializing new probes, to helping Canadians cope with shortages of medical isotopes, CPDC plays an important role in our health care system. Molecular imaging probes and associated technologies have the potential to revolutionize health care. This powerful technology can be used to accelerate and support drug discovery and the development of new therapies by providing researchers and physicians with the unique opportunity to precisely track the movement and effectiveness of drugs in the body. Molecular imaging probes also enable doctors to accurately identify disease, monitor response to treatment and offer personalized treatments that are tailored to the way a disease is progressing and responding within a patient. This approach can lead to better outcomes for patients, lower health care costs and reduced surgical procedures and biopsies. CPDC is unique in that it bridges the gap between university research and clinical programs, helping researchers to move their innovative discoveries from concept to clinical application. Our experienced teams provide expertise to support pre-clinical development of new probes, know-how in regulatory affairs, GMP manufacturing and quality assurance needed to achieve Health Canada approval for clinical trials and commercialization of innovative new products. CPDC is a not-for-profit centre of excellence in research and commercialization that is funded by a five-year grant from the Government of Canada through the Network of Centres of Excellence (NCE) program and an additional grant from the Province of Ontario through the Ontario Institute for Cancer Research.